{"product_id":"qnrx-pestle-analysis","title":"(QNRX) Quoin Pharmaceuticals, Ltd. PESTLE Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePlan Smarter. Present Sharper. Compete Stronger.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Quoin Pharmaceuticals, Ltd. PESTLE Analysis shows how political, economic, social, technological, legal, and environmental forces shape the company’s risks and opportunities; the page includes a real preview of the report so you can judge style and depth—purchase the full version to get the complete, ready-to-use company-specific analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePolitical factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFDA jurisdiction\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eQuoin Pharmaceuticals, Ltd. depends on U.S. FDA review for its rare-disease pipeline, so federal rules on safety, endpoints, and accelerated approval can make or break timelines. In 2025, the FDA approved 50 new drugs, showing how selective the path is. Any delay in FDA feedback can slow financing and weaken partner interest.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e200,000-patient orphan threshold\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eU.S. orphan-drug policy covers diseases affecting fewer than 200,000 people, and Quoin Pharmaceuticals, Ltd.'s focus on Netherton syndrome and dystrophic epidermolysis bullosa fits that rule. Netherton syndrome is ultra-rare, with prevalence often cited at roughly 1 in 200,000 births, while dystrophic epidermolysis bullosa also remains far below the threshold. That keeps Quoin aligned with FDA rare-disease incentives, including 7 years of market exclusivity and tax credits for qualified trials.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOrphan-drug incentives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOrphan-drug incentives matter a lot for Quoin Pharmaceuticals because the U.S. Orphan Drug Act can deliver 7 years of market exclusivity, FDA fee waivers, and a 25% tax credit on qualified clinical trial costs. For a small biotech with no approved product revenue, those tools can cut cash burn and lower the cost of advancing rare-disease programs. They also improve the odds of funding and partnering.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eVirginia business base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eQuoin Pharmaceuticals, Ltd. operates from Ashburn, Virginia, in a state with a deep life-science base and close access to federal regulators in Washington, D.C. Virginia’s 6% corporate income tax and state workforce rules can move operating costs, so policy shifts matter for margins.\u003c\/p\u003e\n\u003cp\u003eLocal pro-business settings in Loudoun County can help with hiring and vendor access, which is important for a small biopharma base. Virginia also keeps its right-to-work law, which supports labor flexibility and can lower hiring friction.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e6% Virginia corporate income tax.\u003c\/li\u003e\n\u003cli\u003eAshburn benefits from Northern Virginia life-science links.\u003c\/li\u003e\n\u003cli\u003eWorkforce and tax policy can affect costs fast.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eGlobal trial approvals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRare-disease trials often need multinational sites because patient pools are tiny; more countries mean more ethics, import, and site approvals. In 2025, the EU still applies a single Clinical Trials Regulation path, but each member state can still slow start-up. Political stability and health-policy fit can cut or add months to enrollment.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMore countries, more approvals\u003c\/li\u003e\n\u003cli\u003eSmall pools force cross-border sites\u003c\/li\u003e\n\u003cli\u003eStable policy speeds enrollment\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFDA and Orphan-Drug Rules Could Make or Break Quoin\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eQuoin Pharmaceuticals, Ltd. is highly exposed to U.S. FDA and orphan-drug policy. In 2025, the FDA approved 50 new drugs, showing how selective the U.S. path stays. Orphan-drug rules can still give 7 years of exclusivity and fee waivers, which matter for a small rare-disease biotech with no product revenue.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eLatest data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA approvals, 2025\u003c\/td\u003e\n\u003ctd\u003e50 new drugs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrphan exclusivity\u003c\/td\u003e\n\u003ctd\u003e7 years\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrphan-drug threshold\u003c\/td\u003e\n\u003ctd\u003eFewer than 200,000 U.S. patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eAnalyzes how Political, Economic, Social, Technological, Environmental, and Legal forces shape Quoin Pharmaceuticals, Ltd.’s risks, opportunities, and strategy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eA concise Quoin Pharmaceuticals PESTLE summary that saves time and clarifies key external risks for faster decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a concise, traceable bibliography of industry reports, clinical data, and regulatory sources to speed due diligence and validate Quoin Pharmaceuticals' key claims.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEconomic factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNo approved revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eQuoin Pharmaceuticals, Ltd. reported no marketed product revenue, so its R and D spend depends on external funding. That puts cash runway and dilution risk at the center of the economic picture: if new capital comes through equity, existing holders face ownership dilution, while a tighter cash position can slow trials and raise financing pressure.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSmall patient pools\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eQuoin Pharmaceuticals, Ltd. targets ultra-rare diseases like Netherton syndrome, which is often cited at about 1 in 200,000 births in the U.S., so the patient pool is tiny. That can support premium pricing if approval comes, but it also keeps the total market small. Revenue forecasts stay very sensitive to how many patients start and stay on treatment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR and D intensity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eQuoin Pharmaceuticals, Ltd. has a high R\u0026amp;D load because QRX003, QRX004, and QRX006 need ongoing trial, manufacturing, and regulatory spend before any sales start. In biotech, R\u0026amp;D often makes up over 50% of operating costs in the clinical stage, so cash burn stays high and margin pressure is normal. If trials slip by even 6-12 months, extra study and CMC costs can force more financing and dilute shareholders.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCapital market volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCapital market volatility is a real funding risk for Quoin Pharmaceuticals, Ltd.: specialty pharma firms often depend on equity raises, warrants, or debt, and sharp share-price swings can lift dilution and borrowing costs fast. When investor risk appetite falls, lenders and PIPE investors usually ask for bigger discounts, so the cost of capital rises and pipeline work can slow.\u003c\/p\u003e\n\u003cp\u003eFor a micro-cap biotech, even a short drop in share price can shrink financing capacity and make each dollar of R\u0026amp;D more expensive. That can force Quoin Pharmaceuticals, Ltd. to delay studies, cut spend, or accept weaker terms. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEquity swings change dilution\u003c\/li\u003e\n\u003cli\u003eWarrants can get pricier\u003c\/li\u003e\n\u003cli\u003eDebt terms can tighten\u003c\/li\u003e\n\u003cli\u003ePipeline timing can slip\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePayer scrutiny\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePayer scrutiny is high even for orphan drugs: U.S. rare-disease medicines often launch above $100,000 a year, so insurers test clinical value and budget impact hard. \u003c\/p\u003e\n\u003cp\u003eFor Quoin Pharmaceuticals, Ltd., that matters because a small patient base can still face steep unit pricing, and weak reimbursement can slow uptake fast. \u003c\/p\u003e\n\u003cp\u003eNet revenue will hinge on coverage terms, prior auth, and how clearly the therapy lowers total care costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eQuoin’s Rare-Disease Promise Comes With High Dilution Risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eQuoin Pharmaceuticals, Ltd. stays cash dependent, with no marketed revenue and heavy R and D burn before sales. For ultra-rare drugs, pricing can be high, but the patient pool is tiny, so uptake and reimbursement drive revenue more than volume. Equity raises, warrants, or debt can add dilution fast if the share price weakens or trials slip.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eEconomic factor\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue base\u003c\/td\u003e\n\u003ctd\u003eNo marketed product sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTarget market\u003c\/td\u003e\n\u003ctd\u003eNetherton syndrome about 1 in 200,000 births\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFunding risk\u003c\/td\u003e\n\u003ctd\u003eHigh dilution risk from equity raises\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eQuoin Pharmaceuticals, Ltd. PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Quoin Pharmaceuticals, Ltd. PESTLE Analysis you’ll receive after purchase—fully formatted, professionally structured, and ready to use with no placeholders or surprises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Social-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eSociological factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUltra-rare disease burden\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNetherton syndrome affects about 1 in 200,000 births, while dystrophic epidermolysis bullosa is roughly 1 in 20,000 births, so Quoin Pharmaceuticals, Ltd. targets very small but high-burden patient groups. Families face daily pain, infection risk, wound care, and school\/work disruption, which makes the disease deeply social as well as medical. That unmet need can speed interest in new therapies, even when patient numbers are tiny.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCaregiver-led decisions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eWith about 20% of U.S. children living with a chronic condition, caregivers often drive rare dermatology treatment choices. For Quoin Pharmaceuticals, Ltd., home-use topical products can fit crowded family routines and reduce clinic burden. Simple dosing also matters because easier use tends to lift adherence and persistence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Social-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient advocacy networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRare-disease advocacy networks matter for Quoin Pharmaceuticals, Ltd. because they connect patients in conditions like Netherton syndrome, which affects about 1 in 200,000 births, and help spread trial news, boost recruitment, and improve disease education. These groups can also raise public pressure for faster access to therapies, which can matter in a market where Quoin had only about $5.0 million in cash and equivalents at 2025 year-end, making efficient patient outreach vital.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eVisible-condition stigma\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVisible skin disease can trigger stigma in school, work, and social life, adding a quality-of-life cost beyond itching or pain. Psoriasis affects about 125 million people worldwide, and around 30% of cases are moderate to severe, where visibility and burden are higher. Effective therapy can improve not just symptoms, but attendance, confidence, and social participation.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eStigma can limit daily participation.\u003c\/li\u003e\n\u003cli\u003eBurden is both medical and social.\u003c\/li\u003e\n\u003cli\u003eTreatment can support quality of life.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePediatric unmet need\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMany orphan dermatology diseases begin in childhood, and rare diseases affect about 300 million people worldwide, with roughly 70% starting before age 18. Families want treatments that children can use long term without heavy burden, so tolerability matters as much as efficacy.\u003c\/p\u003e\n\u003cp\u003eFor Quoin Pharmaceuticals, even small gains in itch, skin-barrier repair, or wound healing can ease daily care, sleep loss, and school disruption. That makes pediatric unmet need a strong social driver of demand.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eChildhood onset raises the need for durable care\u003c\/li\u003e\n\u003cli\u003eLow-burden therapy can matter more than size of effect\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRare Pediatric Skin Disease Care Has Outsized Family and Trial Impact\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRare pediatric skin diseases create daily family burden: pain, infection risk, wound care, sleep loss, and school disruption. In Netherton syndrome, about 1 in 200,000 births are affected, so social impact is high even with tiny patient counts.\u003c\/p\u003e\n\u003cp\u003eCaregivers drive treatment use, so simple home dosing and good tolerability matter. Rare-disease advocacy also helps Quoin Pharmaceuticals, Ltd. with trial awareness and faster recruitment, which is important with about $5.0 million in cash and equivalents at 2025 year-end.\u003c\/p\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Technological-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eTechnological factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTopical QRX003 platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eQRX003 is a topical lotion built for Netherton syndrome, where the skin barrier is highly impaired, so delivery tech matters as much as the active ingredient. In Quoin Pharmaceuticals, Ltd.'s latest public updates through 2025, the program remains a core R\u0026amp;D asset and the main test is whether the lotion can deliver steady absorption with low irritation across damaged skin. Consistency in dosing and tolerability will drive clinical and commercial value.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eQRX004 and QRX006 pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eQuoin Pharmaceuticals, Ltd. is advancing QRX004 and QRX006, so it is not tied to one rare-dermatology asset. That spreads technical risk across separate programs and indications, but it also raises the bar for strong preclinical and clinical proof-of-concept data before capital can scale. In rare disease, even small efficacy signals can move valuation, yet weak readouts can quickly compress it.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Technological-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSmall-n trial design\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eQuoin Pharmaceuticals, Ltd. works in rare diseases, where trial pools are often just a few dozen patients, so small-n design raises real risks around endpoint choice, statistical power, and protocol drift. In these settings, reliable biomarkers and clear clinical measures matter more than ever, because they can support interpretation when patient counts are too low for broad significance. That also means stronger natural-history data and tighter inclusion rules, since even one or two outliers can move results sharply.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eFormulation stability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTopical drugs depend on tight formulation stability: FDA submission packages typically need 6 months of accelerated and 12 months of long-term data, so Quoin Pharmaceuticals, Ltd. must prove shelf life, uniform dosing, and packaging fit. Small shifts in excipients or container closure can change release and skin exposure, so chemistry, manufacturing, and controls work is a core technical risk and cost driver.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eStability data de-risks shelf life\u003c\/li\u003e\n\u003cli\u003eCMC choices can change performance\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRemote data capture\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eQuoin Pharmaceuticals, Ltd.’s rare skin-disease trials face a small, spread-out patient pool, so remote data capture matters. Digital diaries, telemedicine, and home monitoring can cut travel for families and improve visit completion, which is critical when 1 in 10 people lives with a rare disease and trial sites may sit hours away.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBetter trial access\u003c\/li\u003e\n\u003cli\u003eLower family travel load\u003c\/li\u003e\n\u003cli\u003eMore complete data capture\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eQuoin’s QRX003: Delivery Tech Will Make or Break the Drug\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eQuoin Pharmaceuticals, Ltd. depends on formulation and delivery tech as much as the drug itself: QRX003 must work on severely damaged skin with steady absorption and low irritation. Rare-disease trials stay small, so biomarkers, remote capture, and tight protocol control matter. CMC and stability are key too, since even minor excipient or packaging shifts can change skin exposure.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eTech factor\u003c\/th\u003e\n\u003cth\u003eWhy it matters\u003c\/th\u003e\n\u003cth\u003e2025\/2026 data point\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eQRX003 delivery\u003c\/td\u003e\n\u003ctd\u003eAbsorption + irritation\u003c\/td\u003e\n\u003ctd\u003eCore R\u0026amp;D asset\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSmall-n trials\u003c\/td\u003e\n\u003ctd\u003ePower + endpoints\u003c\/td\u003e\n\u003ctd\u003eDozens of patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMC\/stability\u003c\/td\u003e\n\u003ctd\u003eShelf life + dose uniformity\u003c\/td\u003e\n\u003ctd\u003e6m accel, 12m long-term\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Legal-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eLegal factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e7-year orphan exclusivity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn the U.S., an approved orphan drug gets 7 years of market exclusivity, blocking the same use from rival approvals. For Quoin Pharmaceuticals, Ltd., that legal shield can matter more than patent life in rare disease, where patient pools are often below 200,000 and pricing power can improve if the program works. It also raises the value of a successful launch. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFDA pre-approval pathway\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eQuoin Pharmaceuticals, Ltd. must clear FDA pre-approval before any U.S. launch, so it needs strong clinical proof, safety data, and cGMP manufacturing controls. Even one gap can trigger a complete response letter and push launch back by months or longer. For rare-disease programs, that delay can burn cash fast and raise dilution risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Legal-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatent protection\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePatent protection is key for Quoin Pharmaceuticals, Ltd. because coverage for formulations, methods, and delivery can shield pipeline value. For a small company, IP is often the main asset, so weak claims can hit partner and investor confidence. In 2025, biotech dealmaking still favored companies with clear patent life and broad claims, while weak protection raised financing risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eGMP compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eQuoin Pharmaceuticals, Ltd. must keep drug manufacturing under current Good Manufacturing Practice, because cGMP governs batch quality, traceability, and release readiness for clinical supply and future sales. FDA inspections can lead to Form 483 observations or warning letters if controls fail. Vendor oversight and full records are legally critical.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ecGMP protects clinical supply quality.\u003c\/li\u003e\n\u003cli\u003eVendor checks and logs are mandatory.\u003c\/li\u003e\n\u003cli\u003eWeak records raise regulatory risk.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePrivacy and safety reporting\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eQuoin Pharmaceuticals, Ltd.’s clinical work depends on tight control of patient data, informed consent, and adverse-event reporting, because gaps can trigger FDA and IRB scrutiny fast. Under HIPAA, U.S. health data handling can face civil penalties up to $2,134,831 per violation category each year, so strong privacy controls lower legal and reputational risk.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eProtect patient data.\u003c\/li\u003e\n\u003cli\u003eTrack informed consent.\u003c\/li\u003e\n\u003cli\u003eReport adverse events on time.\u003c\/li\u003e\n\u003cli\u003eLimit HIPAA exposure.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eQuoin’s Rare-Disease Moat: 7-Year Exclusivity, Compliance Risks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eQuoin Pharmaceuticals, Ltd. relies on orphan-drug exclusivity, patent scope, and FDA compliance to protect rare-disease value. In the U.S., orphan status can block same-use rivals for 7 years, while cGMP lapses can trigger Form 483s or delay launch. HIPAA penalties can reach $2,134,831 per violation category each year.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eLegal factor\u003c\/th\u003e\n\u003cth\u003eKey number\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrphan exclusivity\u003c\/td\u003e\n\u003ctd\u003e7 years\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHIPAA penalty cap\u003c\/td\u003e\n\u003ctd\u003e$2,134,831\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Enviromental-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEnvironmental factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLow-volume GMP batches\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs a development-stage Company, Quoin Pharmaceuticals, Ltd. likely runs low-volume GMP batches, so its site footprint and energy use can stay below large-scale pharma levels. Even so, small runs need tight waste control, because each failed batch can raise solvent, API, and packaging waste fast. This matters as the Company moves from R\u0026amp;D toward any 2025-2026 clinical supply scale-up.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eChemical waste handling\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFormulation and lab work at Quoin Pharmaceuticals, Ltd. can create solvent, packaging, and biohazard waste, and U.S. EPA hazardous-waste rules can carry penalties of up to $81,540 per day per violation in 2025. Poor segregation or disposal can also raise treatment costs because hazardous waste handling is far pricier than regular trash. Tight tracking and vendor controls lower compliance and cost risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Enviromental-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePackaging materials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eQuoin Pharmaceuticals, Ltd. relies on tubes, containers, and secondary packaging for topical products and clinical supplies, so material choice directly drives waste and recyclability. In 2025, pharma packaging demand kept shifting to recyclable mono-materials and lower-plastic formats as procurement teams tracked Scope 3 emissions and supplier ESG scores. With global plastic waste still above 350 million tonnes a year, sustainable sourcing is now a real cost and compliance issue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eVirginia weather risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAshburn, Virginia faces heat, thunderstorms, and occasional severe weather, with Washington Dulles-area climate normals showing July highs near 87°F and January lows near 25°F. For Quoin Pharmaceuticals, Ltd., that can disrupt office work, shipment timing, and trial logistics, so business continuity planning is important even for a small team.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHeat and storms can halt operations\u003c\/li\u003e\n\u003cli\u003eShipments and trial runs can slip\u003c\/li\u003e\n\u003cli\u003eBackup plans reduce small-company risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSupply-chain emissions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eClinical development depends on cross-border shipping of samples, kits, and trial supplies, so Quoin Pharmaceuticals, Ltd. faces Scope 3 pressure from transport emissions. Air freight can emit roughly 500 gCO2e per tonne-km, while sea freight is often near 10-40 gCO2e, so mode choice changes carbon intensity fast. Freight delays also affect trial timing and inventory buffers.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTrack shipment-level emissions\u003c\/li\u003e\n\u003cli\u003ePrefer lower-carbon freight modes\u003c\/li\u003e\n\u003cli\u003eBuild delay buffers into plans\u003c\/li\u003e\n\u003cli\u003eReport Scope 3 cuts clearly\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eQuoin’s real ESG risk: waste, freight, and packaging\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eQuoin Pharmaceuticals, Ltd. faces low direct energy use, but its real environmental risk sits in batch waste, solvent handling, and packaging. U.S. EPA hazardous-waste penalties can reach $81,540 per day per violation in 2025, so tight segregation and vendor controls matter.\u003c\/p\u003e\n\u003cp\u003eClimate and logistics also matter: Ashburn storms can disrupt supply, and freight choice drives Scope 3 emissions, with air near 500 gCO2e per tonne-km versus sea at 10-40. Packaging pressure is rising too, as global plastic waste tops 350 million tonnes a year.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHazardous waste\u003c\/td\u003e\n\u003ctd\u003e$81,540\/day\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFreight emissions\u003c\/td\u003e\n\u003ctd\u003e500 vs 10-40 gCO2e\/t-km\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlastic waste\u003c\/td\u003e\n\u003ctd\u003e350M+ tonnes\/year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234835800329,"sku":"qnrx-pestle-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/qnrx-pestle-analysis.webp?v=1785729533","url":"https:\/\/dcfanalyst.com\/products\/qnrx-pestle-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}